The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Osmanov Yu.I.

Department of Pathoanatomy, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;
Department of Pathoanatomy, Research Clinical Center, OAO RZhD, Moscow, Russia

Gaibov Zh.A.

Department of Pathoanatomy, Research Clinical Center, OAO RZhD, Moscow, Russia

Kogan E.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova, Moskva

Radenska-Lopovok S.G.

FGBU "Nauchno-issledovatel'skiĭ institut revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Tursunov Kh.Z.

Department of Pathoanatomy, Tashkent Medical Academy, Tashkent, Respublica Uzbekistan

Morphological and immunohistochemical characteristics of the molecular subtypes of urothelial carcinomas

Authors:

Osmanov Yu.I., Gaibov Zh.A., Kogan E.A., Radenska-Lopovok S.G., Tursunov Kh.Z.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2019;81(5): 35‑44

DOI: 10.17116/patol20198105135

Views: 1431

Downloaded: 68

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Osmanov YuI, Gaibov ZhA, Kogan EA, Radenska-Lopovok SG, Tursunov KhZ. Morphological and immunohistochemical characteristics of the molecular subtypes of urothelial carcinomas. Russian Journal of Archive of Pathology. 2019;81(5):35‑44. (In Russ.)
https://doi.org/10.17116/patol20198105135

Подписка 2025 (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Close metadata

The molecular subtypes of urothelial carcinoma in each classification scheme have characteristic immunohistochemical features. At the same time, the results of conducted studies often demonstrate a discrepancy between the genomic profile of urothelial carcinoma and its immunophenotype, which complicates the immunohistochemical verification of the molecular subtypes of these tumors. Objective — to compare the morphological and immunophenotypic characteristics of the molecular subtypes of urothelial carcinoma. Material and methods. Surgical specimens from 196 patients diagnosed with urothelial carcinoma of the renal pelvis and bladder were investigated. Paraffin-embedded sections were immunohistochemically examined using the standard protocol. Antibodies against CK5/6, CK17, Rb1 (Dako), CK14, CK18, CK20, Cyclin D1, Cyclin E1, Cyclin A, Cyclin B, Chromogranin, E-Cadherin, P-Cadherin, p16, Uroplakin II, TUBB2B, Vimentin, ZEB-2 («Novocastra»), CD44, GATA-3, and Uroplakin III («Cell Marque») were used. Results. Out of 68 (35%) superficial papillary urothelial carcinomas, 24 (12%) tumors constituted Molecular Class I and 12 (6%) and 32 (16%) ones did Molecular Classes II and III, respectively. Of the 128 (65%) muscle-invasive urothelial carcinomas, 57 (29%) tumors were referred to as the luminal-papillary molecular subtype, and 24 (12%) and 14 (7%) were as the luminal-infiltrated and luminal molecular subtypes, respectively. The basal squamous molecular subtype was verified in 31 (16%) neoplasms and the neuronal phenotype was detected in 2 (1%) cases. Conclusion. Most pT1 tissues correspond to Molecular Class II. In the muscle-invasive urothelial carcinoma group, the neoplasms with a luminal phenotype predominate over the tumors with basal and neuronal phenotypes.

Keywords:

urothelial carcinoma
renal pelvis
bladder
immunoprofile
molecular classification

Authors:

Osmanov Yu.I.

Department of Pathoanatomy, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;
Department of Pathoanatomy, Research Clinical Center, OAO RZhD, Moscow, Russia

Gaibov Zh.A.

Department of Pathoanatomy, Research Clinical Center, OAO RZhD, Moscow, Russia

Kogan E.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova, Moskva

Radenska-Lopovok S.G.

FGBU "Nauchno-issledovatel'skiĭ institut revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Tursunov Kh.Z.

Department of Pathoanatomy, Tashkent Medical Academy, Tashkent, Respublica Uzbekistan

List of references:

  1. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, Gudjonsson S, Liedberg F, Patschan O, Månsson W, Fernö M, Höglund M. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012;7(6):e38863. https://doi.org/10.1371/journal.pone.0038863
  2. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152-165. https://doi.org/10.1016/j.ccr.2014.01.009
  3. Carrington JC, Ambros V. Role of microRNAs in plant and animal development. Science. 2003;301(5631):336-338. https://doi.org/10.1126/science.1085242
  4. Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851-4860. https://doi.org/10.1158/0008-5472.CAN-08-4043
  5. Damrauer JS, Hoadley KA, Chism DD, Fan Ch, Tiganelli ChJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 2014;111(8):3110-3115. https://doi.org/10.1073/pnas.1318376111
  6. Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377-3386. https://doi.org/10.1158/1078-0432.CCR-12-0077-T
  7. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature.2014;507(7192):315-322. https://doi.org/10.1038/nature12965
  8. Eriksson P, Aine M, Veerla S, Liedberg F, Sjödahl G, Höglund M. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. BMC Med Genomics. 2015;8:25. https://doi.org/10.1186/s12920-015-0101-5
  9. Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classification. J Pathol. 2017;242(1):113-125. https://doi.org/10.1002/path.4886
  10. Inamura K. Bladder cancer: new insights into its molecular pathology. Cancers (Basel). 2018;10(4):100. https://doi.org/10.3390/cancers10040100
  11. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-56.e25. https://doi.org/10.1016/j.cell.2017.09.007
  12. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. 4th ed. Eur Urol. 2016;70(1):106-119. https://doi.org/10.1016/j.eururo.2016.02.028
  13. Lopez-Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol. 2006;37(11):1371-1388. https://doi.org/10.1016/j.humpath.2006.05.009
  14. Amin MB, Grignon DJ, Srigley JR, Eble JN. Urological pathology. Lippincott Williams and Wilkins; 2015:261-461.
  15. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009;22(Suppl.2):70-95. https://doi.org/10.1038/modpathol.2009.1
  16. Rajcani J, Kajo K, Adamkov M, Moravekova E, Lauko L, Felcanova D, Bencat M. Immunohistochemical characterization of urothelial carcinoma. Bratisl Lek Listy. 2013;114(8):431-438.
  17. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. Bladder cancer. Nat Rev Dis Prim. 2017;3:17022. https://doi.org/10.1038/nrdp.201722
  18. Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, Vang S, Reinert T, Hermann GG, Mogensen K, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30:27-42. https://doi.org/10.1016/j.ccell.2016.05.004
  19. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-1920. https://doi.org/10.1016/S0140-6736(16)00561-4
  20. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495-501. https://doi.org/10.1038/nature12912
  21. Aine M, Eriksson P, Liedberg F, Höglund M. On molecular classification of bladder cancer: out of one, many. Eur Urol. 2015;68(6):921-923. https://doi.org/10.1016/j.eururo.2015.07.021
  22. Rebouissou S, Bernard-Pierrot I, de Reynie`s A, Lepage M-L, Krucker C. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014;6:244ra91. https://doi.org/10.1126/scitranslmed.3008970
  23. Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim W, Radvanyi F, Höglund M, Real FX. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer. 2016;2(1):37-47. https://doi.org/10.3233/BLC-150037 Received 15.01.19

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.